Guardian Pharmacy holders report 43.9% Class A stake

Q: How many GRDN shares do the reporting persons beneficially own?

The reporting persons collectively beneficially own 27,822,550 shares of Class A common stock, approximately 43.9% of the class. The percentage is calculated using 63,320,300 Class A shares outstanding as of September 27, 2026.

Q: Which shares are excluded from David K. Morris’s reported GRDN holdings?

641,870 shares of Class A common stock are excluded. David K. Morris agreed to transfer those shares on or before November 11, 2026, pursuant to a September 2025 domestic relations order.

The automatic conversion issued 13,521,396 Class A shares in exchange for an equal number of Class B shares on September 27, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

SCHEDULE 13D/A

Rhea-AI Filing Summary

For Guardian Pharmacy Services, Inc. (GRDN), the issuer, the reporting persons collectively beneficially own 27,822,550 shares of Class A common stock, approximately 43.9% of the class. The reporting persons are Bindley Capital Partners I, LLC, William E. Bindley, Thomas J. Salentine, Jr., Pharmacy Investors, LLC, John Ackerman, Cardinal Equity Fund, L.P., Fred P. Burke, David K. Morris and G. Kendall Forbes.

Class A shares outstanding were 63,320,300 as of September 27, 2026; that day, 13,521,396 Class A shares were issued upon automatic conversion of an equal number of Class B shares. Thomas J. Salentine, Jr. directly owns 35,714 shares. David K. Morris’s reported holdings exclude 641,870 shares he agreed to transfer on or before November 11, 2026, under a September 2025 domestic relations order.

Key Figures

Reporting persons’ collective beneficial ownership: 27,822,550 shares Collective ownership percentage: Approximately 43.9% Class A shares outstanding: 63,320,300 shares +3 more

6 metrics

Reporting persons’ collective beneficial ownership 27,822,550 shares Class A common stock

Collective ownership percentage Approximately 43.9% Calculated using 63,320,300 Class A shares outstanding

Class A shares outstanding 63,320,300 shares As of September 27, 2026

Class A shares issued upon automatic conversion 13,521,396 shares September 27, 2026; converted from an equal number of Class B shares

Thomas J. Salentine, Jr. direct ownership 35,714 shares Class A common stock

Shares excluded from David K. Morris’s reported holdings 641,870 shares Agreed transfer on or before November 11, 2026

Key Terms

beneficially own, automatic conversion, domestic relations order, shared voting power, +1 more

5 terms

beneficially own regulatory

"collectively beneficially own 27,822,550 shares of Class A common stock"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

automatic conversion technical

"issued upon the automatic conversion of an equal number"

domestic relations order regulatory

"pursuant a September 2025 domestic relations order"

shared voting power regulatory

"Shared Voting Power 16,669,666.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

sole dispositive power regulatory

"Sole Dispositive Power 16,669,666.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GRDN shares do the reporting persons beneficially own?

The reporting persons collectively beneficially own 27,822,550 shares of Class A common stock, approximately 43.9% of the class. The percentage is calculated using 63,320,300 Class A shares outstanding as of September 27, 2026.

How many GRDN Class B shares converted to Class A?

13,521,396 Class A shares were issued upon automatic conversion of an equal number of Class B shares on September 27, 2026, pursuant to Guardian Pharmacy Services, Inc.’s Amended and Restated Certificate of Incorporation.

Which shares are excluded from David K. Morris’s reported GRDN holdings?

641,870 shares of Class A common stock are excluded. David K. Morris agreed to transfer those shares on or before November 11, 2026, pursuant to a September 2025 domestic relations order.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/28/2026 - 05:03 PM Accepted by SEC EDGAR 09/28/2026 - 05:02 PM

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

Guardian Pharmacy Services, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.001 per share

(Title of Class of Securities)

40145W101

(CUSIP Number)

Bindley Capital Partners I LLC
(Attn: William E. Bindley), 8909 Purdue Road, Suite 500
Indianapolis, IN, 46268
(317) 704-4162

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/27/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Class A Common Stock, par value $0.001 per share

(b)

Name of Issuer:

Guardian Pharmacy Services, Inc.

(c)

Address of Issuer's Principal Executive Offices:

300 Galleria Parkway SE, Suite 800, Atlanta, GEORGIA , 30339.

Item 1 Comment:

EXPLANATORY NOTE: This Schedule 13D serves as Amendment No. 4 ("Amendment No. 4") to the Statement on Schedule 13D initially filed by the Reporting Persons (as defined below) on February 3, 2025, as amended by Amendment No. 1 thereto filed on May 29, 2025, Amendment No. 2 thereto filed on July 29, 2025, and Amendment No. 3 thereto filed on March 24, 2026 (and as further amended by this Amendment No. 4, the "Schedule 13D"). Except as specifically provided herein, this Amendment No. 4 does not modify any information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 4 shall have the same meanings herein as are ascribed to such terms in the Schedule 13D. This Amendment No. 4 is being jointly filed by Bindley Capital Partners I, LLC ("Bindley Capital"), William E. Bindley, Thomas J. Salentine, Jr., Pharmacy Investors, LLC ("Pharmacy Investors"), John Ackerman, Cardinal Equity Fund, L.P. ("Cardinal"), Fred P. Burke, David K. Morris and G. Kendall Forbes (each a "Reporting Person," and collectively, the "Reporting Persons").

Item 3.

Source and Amount of Funds or Other Consideration

As of the date hereof, the Reporting Persons, collectively, beneficially own 27,822,550 shares of Class A common stock.

Item 5.

Interest in Securities of the Issuer

(a)

As of the date hereof, the Reporting Persons, collectively, beneficially own 27,822,550 shares of Class A common stock, representing approximately 43.9% of the shares of Class A common stock, calculated based on 63,320,300 shares of Class A common stock outstanding as disclosed in the 8-K. Of the 63,320,300 shares of Class A common stock currently outstanding, 13,521,396 shares of Class A common stock were issued upon the automatic conversion of an equal number of shares of the Issuer's Class B common stock, par value $0.001 per share, on September 27, 2026, pursuant to the Issuer's Amended and Restated Certificate of Incorporation.

(b)

The aggregate number and percentage of shares of Class A common stock beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares of Class A common stock as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on Rows 7 through 11 and Row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference.

(c)

Except as set forth in the Schedule 13D, no transactions in the shares of Class A common stock were effected by the Reporting Persons, or, to the knowledge of the Reporting Persons, any of the persons listed on Schedule A hereto in the 60 days preceding the date of the Schedule 13D.

(d)

Except as described herein, to the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of Class A common stock of the Issuer beneficially owned by the Reporting Persons as described in this Item 5.

(e)

Not applicable.

Item 7.

Material to be Filed as Exhibits.

Exhibit 99.1 Stockholders' Agreement, dated as of September 25, 2024, by and among Guardian Pharmacy Services, Inc., Bindley Capital Partners I, LLC, Pharmacy Investors, LLC, Cardinal Equity Fund LP, Fred Burke, David Morris and Kendall Forbes (incorporated by reference to Exhibit 4.1 of the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 30, 2024). Exhibit 99.2 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Exchange Act (incorporated by reference to the Schedule 13D filed with the Securities and Exchange Commission on February 3, 2025).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bindley Capital Partners I, LLC

Signature:	/s/ Thomas J. Salentine, Jr.
Name/Title:	Member
Date:	09/28/2026

William E. Bindley

Signature:	/s/ William E. Bindley, individually
Name/Title:	William E. Bindley, individually
Date:	09/28/2026

Thomas J. Salentine, Jr.

Signature:	/s/ Thomas J. Salentine, Jr., individually
Name/Title:	Thomas J. Salentine, Jr., individually
Date:	09/28/2026

Pharmacy Investors, LLC

Signature:	/s/ John Ackerman
Name/Title:	Managing Member
Date:	09/28/2026

John Ackerman

Signature:	/s/ John Ackerman, individually
Name/Title:	John Ackerman, individually
Date:	09/28/2026

Cardinal Equity Fund, L.P.

Signature:	/s/ John Ackerman, by Cardinal Equity Partners, LLC, its General Partner
Name/Title:	Managing Member
Date:	09/28/2026

Fred P. Burke

Signature:	/s/ Fred P. Burke, individually
Name/Title:	Fred P. Burke, individually
Date:	09/28/2026

David K. Morris

Signature:	/s/ David K. Morris, individually
Name/Title:	David K. Morris, individually
Date:	09/28/2026

G. Kendall Forbes

Signature:	/s/ G. Kendall Forbes, individually
Name/Title:	G. Kendall Forbes, individually
Date:	09/28/2026

Source: View Original Filing on SEC EDGAR